Eumovate® (Clobetasone Butyrate 0.05% Cream and Ointment) - A - Detailing from Skin Therapy Letter

 

Eumovate® (Clobetasone Butyrate 0.05% Cream and Ointment)

 

 

  Content:

COMPLIANCE

 

 

  • Reasons for treatment failure in atopic eczema:
    • failure to use the topical corticosteroid due to fear of real or imagined side-effects
    • under prescribing/failure to use sufficient quantity
    • failure to renew prescription in time.
  • It is very important that patients/caregivers understand the safety and potential side effects for moderate potency topical corticosteroids such as Eumovate®. Misconceptions about commonly prescribed topical corticosteroid preparations among parents/caregivers include:
    • 44% graded hydrocortisone as a potent steroid.
    • 42% did not grade betamethasone valerate 0.1% as potent.
    • 29% graded clobetasone butyrate 0.05% (Eumovate®) as potent.
    • 12% graded clobetasone butyrate 0.05% (Eumovate®) as weak.
    • [Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of atopic dermatitis. Clin Exp Dermatol. 2003 Sep;28(5):549-53.]

  • Patient education on topical steroids is clearly needed

Next:   Side Effects, Safety and Risks